Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | March 16, 2016

The Eve of a Paradigm Shift in Cardiology?

While there are constant advances in cardiac technologies, it is rare when one of these new ideas may rapidly challenge the standard of care in a very short period of time. However, that is exactly what has happened with the introduction of transcatheter aortic valve replacement (TAVR). In a few short years since the U.S. Food and Drug Administration’s (FDA) market clearance of the Edwards Lifesciences’ Sapien valve in 2011 and Medtronic’s CoreValve in 2012, both these devices have shown vast improvements in survival for very sick, inoperable patients. Results were also outstanding for extreme-risk and high-risk surgical patients. The CoreValve has data showing it outperforms surgical repair in patient outcomes. This has made many experts wonder if there will soon be a paradigm shift in care, when the question switches from which patients qualify for TAVR, to which patients would actually benefit from open-heart surgical aortic valve replacement (SAVR) over TAVR.

That great question has been limited up until now for very sick patients, but both devices are about to start FDA investigational device exemption (IDE) studies in 2016 to see if low-risk surgical patients fare better with TAVR than SAVR. These two trials will undoubtedly be the next blockbuster, late-breaking studies that cardiologists will be waiting on the edge of their seats for.  This is the cardiology equivalent of a Hollywood blockbuster movie where fans camp in front of the theaters for days waiting to be the first in line to see the premier.

The FDA approved expanded indication trials for low-risk surgical patients using the Sapien 3 device in January and CoreValve Evolut R in February. Patients with aortic stenosis, who are at a low surgical mortality risk as determined by a heart team, will be enrolled in these trials.

If these trials show TAVR outcomes are at least equal to SAVR, open-heart valve surgery will likely see a rapid demise in the coming years. However, the final nail in the coffin for SAVR will only come after long-term follow-up. That data is needed to show the durability of TAVR valves over many years.

Come by and say “hello” to me at future TCT and ACC meetings when those presentations occur.  You will find me camped out the night before in front of the doors to the main arena so I have a front row seat at the premier.

For more details on the shift in care toward  TAVR, watch my video interview with Michael Reardon, M.D., about  TAVR having better outcomes than SAVR at http://bit.ly/1n6OvHe.

Watch the VIDEO “How to Build An Integrated Heart Team.” Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance of building a good heart team and how that team should interact. 

Related Content

Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
TherOx Receives FDA Approval for SuperSaturated Oxygen Therapy
Technology | Cath Lab | April 08, 2019
TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its...
Overlay Init